Psoriasis is a chronic, noncontiguous, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. There is a genetic predisposition to psoriasis and has tendency to wax and wane with flares related to systemic or environmental factors, including life stress events and infection.
Recommendations for topical treatments in treatment of psoriasis
Psoriasis is a common dermatologic disease, affecting approximately 0.3-2.5% of the population (Plunkett and Marks, 1998) . Plaque psoriasis is the most common form, accounting for approximately 90% of cases. The disease is usually chronic and persistent, although up to 50% of patients may enter spontaneous remission for varying periods of time.
Psoriasis has a significant impact on patient quality of life. The social and psychological impact is considerable. Psoriasis is not considered a life-threatening disease, but it is well established that those patients may experience a range of psychosocial difficulties, including elevated levels of anxiety, depression, and worry (Richards and Fortune, 2006) .
The etiopathogenesis of psoriasis is still not fully understood and involves a complex interaction of genetic and environmental factors. Psoriasis was originally thought to be a keratinisation disorder, but now substantial evidence indicates that different components of the innate-and acquired-immunity (T cells, dendritic cells, and inflammatory cytokines) are critically involved in initiating and maintaining the inflammatory response (Tagami and Aiba, 1997; Jullien, 2006) .
There is no cure for psoriasis; therefore, the aim of treatment is to minimize the extent and severity of the disease to the point at which it no longer substantially disrupts the patient's quality of life (Fairhurst et al., 2005) .
Topical therapy is the mainstay of treatment for mild to moderate psoriasis and often the initial treatment for severe psoriasis (Ashcroft et al., 2000) .
About 80% of patients with psoriasis are treated topically (Peeters et al., 2005) . Patients treated with phototherapy or systemic agents, including biological agents, can also be managed with topical agents as adjunctive therapy (Guenther et al., 2004) .
First-line therapy of psoriasis usually consists of topical agents, such as emollients, tar, dithranol, corticosteroids and vitamin D3 analogues. In cases of severe, extensive psoriasis, where topical therapy is either impractical or not sufficiently effective, phototherapy or systemic treatment may be warranted at the outset.
The majority of patients with psoriasis have limited disease (<5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-tosafety ratio.
In this guideline of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis. We will discuss the efficacy and safety as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tacrolimus, pimecrolimus, salicylic acid, anthralin, coal tar, as well as combination therapy.
Method
A work group of expert dermatologists from different locations in Saudi Arabia set to determine the scope of the guideline and to identify best data from American Academy of Dermatology (AAD) (Menter et al., 2009) and German guideline (Nast et al., 2007) and adopted it according to team experience. So we have utilized expert opinion to generate this clinical guideline.
Before use of this guideline
This guideline is intended for dermatologists in private and government hospitals as well as for other specialties involved in the treatment of psoriasis. All physicians follow the recommendations contained in this guideline under their own risk.
Topical treatments for psoriasis
Topical therapy forms the cornerstone in the management of psoriasis. Of significant value as monotherapy in mild to moderate psoriasis, it is used predominantly as adjunctive therapy in moderate and severe forms of the disease. These are medicines in creams, ointments and lotions that are applied to the skin and scalp. There are a number of different approaches possible. Here are some of the most common topical treatments.
Corticosteroids
Topical steroids are the most commonly prescribed medicine for psoriasis. They are the primary treatment strategy for most mild to moderate cases of psoriasis. Because of the increased skin surface/body mass ratio, the risks to infants and children may be higher for systemic effects secondary to enhanced absorption. Growth retardation is also a potential concern. In children mid-potent steroids could be sufficient. Caution especially on the face.
The mechanisms of action of corticosteroids include antiinflammatory, anti proliferative, immunosuppressive, and vasoconstrictive effects. These effects are mediated through their binding to intracellular corticosteroid receptors and regulation of gene transcription of numerous genes, particularly those that code for proinflammatory cytokines (Cornell and Stoughton, 1985) .
Topical corticosteroids come in different strengths designed for use on different parts of the body. Stronger potency steroids might be necessary for tough to treat patches of psoriasis on the elbows or knees. Weaker formulas are good for more sensitive skin on the face or groin.
Steroids can cause side effects, such as thinning of the skin, changes in the skin color, bruising, and dilated blood vessels. Occlusion may increase these side effects (Koo and Lebwohl, 1999; Pierard et al., 1989) .
Recommendations for the use of topical corticosteroids are shown in Table 1 .
Vitamin D analogues
Calcipotriol is a vitamin D3 analogue that is as potent as calcitriol in inhibiting cell proliferation and inducing cell differentiation in vitro but is at least 100 times less active than calcitriol in its effect on calcium metabolism in rats (Binderup and Bramm, 1988) . During the last decade, calcipotriene has emerged as an effective topical therapy for psoriasis (Kragballe et al., 1988 (Kragballe et al., , 1991 Highton and Quell, 1995; Lea and Goa, 1996) .
The mechanism of action of the vitamin D analogues in psoriasis is believed to be mediated by their binding to vitamin D receptors, which leads to both the inhibition of keratinocyte proliferation and the enhancement of keratinocyte differentiation.
Irritation is the most common adverse event associated with calcipotriene use occurring in 15-25% of patients, it may necessitate withdrawal of treatment (Lea and Goa, 1996) .
Recommendations for the use of vitamin D analogues are shown in Table 2 .
Combination of calcipotriol/betamethasone dipropionate ointment
This new two-compound ointment is a combination of calcipotriol 50 lg/g and betamethasone dipropionate 0.5 mg/g in a single vehicle (5% polyoxypropylene-15-stearyl ether) achieving optimal delivery of both drugs in an active state into the skin (Simonsen et al., 2004) , without affecting each other's absorption (Hansen et al., 2001; Guenther, 2005) and it is stable and active for more than 2 years at room temperature (Traulsen, 2004) .
The combination of calcipotriol with a corticosteroid improves efficacy and decreases skin irritation. Two studies showed that the administration of the combination of calcipotriol and betamethasone dipropionate for a 4-week period improved keratinocyte proliferation, differentiation (Van Rossum et al., 2001; Vissers et al., 2004) , and inflammatory characteristics (Vissers et al., 2004) . Also this new twocompound ointment induces a steroid-sparing effect in longterm treatments and thereby reduces the risk of skin atrophy and skin thickness (Traulsen and Hughes-Formella, 2003) , stretch marks, telangiectasia, rebound phenomenon, and tachyphylaxis.
Calcipotriol/betamethasone dipropionate combination ointment used once daily is well tolerated and more effective in treatment of psoriasis than either active constituent used alone (Kaufmann et al., 2002) . Calcipotriol/betamethasone dipropionate has been shown to be effective in mild-to moderate psoriasis. It has been shown to be safe and effective in the treatment of psoriasis vulgaris.
Recommendations for the use of vitamin D analogues are shown in Table 3 .
Calcineurin inhibitors
Tacrolimus ointment and pimecrolimus cream are approved in the United States for treatment of atopic dermatitis. Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants (Reynolds and Al-Daraji, 2002) . Calcineurin inhibitors function by blocking the synthesis of numerous inflammatory cytokines that play an important role in the pathogenesis of psoriasis.
In the treatment of psoriasis, the topical use of tacrolimus and pimecrolimus has promise (Ruzicka et al., 2003) . However, neither medication has yet to be approved by the FDA for this indication.
Neither tacrolimus ointment (Lazarous and Kerdel, 2002 ) nor pimecrolimus (Gupta and Chow, 2003) cream appear effective for treating plaque-type psoriasis when simply applied as commercially available. No information on excretion in breast milk; pregnant and nursing mothers were excluded from clinical studies Pediatric use Appears to be safe between ages 2-14 years with maximum 50 g/week Occlusion makes topical tacrolimus (Remitz et al., 1999 ) and pimecrolimus (Paul et al., 2000) more effective in treating psoriasis, suggesting that there was a lack of penetration through the thick psoriatic plaque. This led to the concept of utilizing the topical calcineurin inhibitors in thinner skin areas such as facial and intertriginous psoriasis with no evidence of resultant skin atrophy as compared with the use of topical corticosteroids in these regions.
The most common side effect for both medications is burning and itching that generally reduces with ongoing usage and can also be mitigated by not applying immediately after bathing. This side effect appears to be more significant in patients treated with tacrolimus ointment as compared with patients treated with pimecrolimus cream.
Recommendations for the use of topical tacrolimus and pimecrolimus are shown in Table 4 . 
Salicylic acid
Keratolytic agent Salicylic acid is the most widely used keratolytic agent in psoriasis. It softens the scaly layers of psoriatic plaques and eases their removal. It is applied to palms, soles and scalp in concentrations of 2-10%. Salicylic acid is especially useful in combination with corticosteroids to enhance penetration and improve clinical efficacy (Federman and Fraelish, 1999) . Salicylic acid is an irritant and, when used extensively at high concentrations, can lead to salicylate toxicity.
Recommendations for the use salicylic acid are shown in Table 5 .
Anthralin
Anthralin[1,8-dihydroxy-9(10H)-anthracenone, dithranol] was first synthesized as a derivative of chrysarobin, prepared from the araroba tree, and is an established, safe, and effective topical treatment for psoriasis (Marsden et al., 1983) .
It is one of few topical treatments to induce clearance of psoriatic plaques, leading to a period of remission, although its widespread use is limited by local irritation and staining. Anthralin inhibits proliferation of mouse and human keratinocytes as well as psoriatic keratinocytes in vivo (Hayden et al., 1994; Baxter and Stoughton, 1970) , but its mechanism of action in psoriasis remains incompletely understood and its molecular target(s) are unknown.
The most common side effects of anthralin are skin irritation and staining of lesional and adjoining skin, nails, clothing, and other objects with which patients come into contact.
Recommendations for the use of topical anthalin are shown in Table 6 .
Coal tar
Coal tar is produced by the primary condensation during corbonization of coal (Gruber et al., 1970) . In 1931 Goeckerman popularised his therapy of coal tar in psoriasis (Goeckerman, 1931) . Although the mechanism of action of coal tar is not well -Data are limited on salicylic acid used alone -Comparator study of tacrolimus and salicylic acid versus tacrolimus alone in small study (N = 24) of psoriasis patients with 10% BSA revealed improved efficacy with addition of salicylic acid. Comparator study of 408 patients with moderate to severe psoriasis treated with mometasone and salicylic acid versus mometasone alone for 3 weeks; psoriasis severity index measures erythema, indurations, and scaling showed the combination of mometasone furoateesalicylic acid to be more effective than mometasone furoate alone Adverse drug reaction/ contraindication Systemic absorption, although rare, can occur, especially when applied to more than 20% of BSA or in patients with abnormal hepatic or renal function Drug interaction Do notcombine salicylic acid with other salicylate drugs and also with vitamin D3 analogues Salicylic acid decreases the efficacy of UVB phototherapy because of a filtering effect and should not be used before UVB phototherapy Baseline monitoring None Pregnancy/nursing Appears to be a safe choice for the control of localized psoriasis in pregnancy Pediatric use
Because of greater risk of systemic absorption and toxicity, salicylic acid should be avoided in children understood, it is known to suppress DNA synthesis by lessening the mitotic labeling index of keratinocytes. Many formulations of coal tar exist, and standardization of these products is not always ideal. In one small study of 18 patients, 5% liquor carbonis detergens was more effective than its emollient base in the treatment of psoriasis (Kanzler and Gorsulowsky, 1993) .
Side-effects of tar include folliculitis, irritation, and photosensitivity. It should not be used on acutely inflamed skin, or on pustular or erythrodermic psoriasis (Comaish, 1981) .
There is no definitive evidence of an increased risk of skin cancer above the expected incidence for the general population from the use of therapeutic tar (Pion et al., 1995; Pittelkow et al., 1981) .
Education regarding the favorable safety profile and place in therapy as a steroid-sparing adjunct may increase tolerance and compliance of this excellent and underutilized topical therapy.
Recommendations for the use of topical Coal tar are shown in Table 7 .
Emollient
Emollient therapy describes the application of moisturisers which are used to make the skin less scaly and dry. Often the words emollient and moisturiser are used interchangeably. Emollients or moisturizers can act as an important adjunctive therapy of topical treatment in psoriatic patients. The use of an emollient can limit relapses after the end of corticosteroid therapy, and maintain the improvement obtained after 1 month corticosteroid therapy at clinical level (physician global assessment) and skin dryness (Seite´et al., 2009 ). There are numerous other non-medicated topical moisturizer compounds and formulations available; depending on the individual product, they can be applied up to several times daily. The goal of treatment with these agents is to provide and retain moisture in the stratum corneum; these agents are thought to function by forming a film on the skin surface to help retain moisture. There are no known contraindications to the use of these non-medicated moisturizers; the large majority of these agents are considered safe during pregnancy and lactation as well as for pediatric use. Recommendations for the use of emollients are shown in Table 8 .
Conclusion
Great advances have been made in the understanding of the pathogenesis of psoriasis and this has led to the use of new therapies for patients.
The aim of these guidelines is to help the dermatologist to know more about different types of topical therapies and to reduce toxicity and side effects. Topical therapies still have a vital role to play in the management of psoriasis. The letter class of drugs possesses better efficacy and a better patient acceptability profile. In double-blind, randomized, controlled trial of 324 patients with mild to moderate psoriasis comparing 1% coal tar lotion with 5% coal tar extract, there was better improvement in both PASI score and Total Sign Score in patients treated with 1% lotion than in 5% extract Adverse drug reaction/ contraindication -Often poorly tolerated by patients because of cosmetic issues, including staining of clothes and tar odor;
other potential adverse events include irritant contact dermatitis, folliculitis, and photosensitivity -Coal tar is carcinogenic in animals, but in humans, there are no convincing data proving carcinogenicity, and epidemiologic studies fail to show increased risk of skin cancer in patients who use coal tar Drug interaction -Not known with topical use -Attention should be paid to the concomitant intake of oral photosensitizing systemic drugs Baseline monitoring None Pregnancy/nursing Coal tar products are contraindicated during pregnancy and nursing Pediatric use Use with caution , Berends, M., Muys, L., et al., 2004 . The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subset in chronic plaque psoriasis. Exp. Dermatol. 13, 106-112.
